Physician profile
Daniel C Byron
NPI 1871943910
$3,286.15
in general payments reported to CMS, 2019-2025
21 companies · $740 in 2025
The $740 reported for 2025 was more than what 86% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $421 · 2020: $215 · 2021: $485 · 2022: $567 · 2023: $338 · 2024: $520 · 2025: $740.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,598.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,598.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $511.17 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Sun Pharmaceutical Industries INC. | $446.37 | 2019-2025 | Cequa |
| Novartis Pharmaceuticals Corporation | $327.21 | 2019-2023 | |
| Alcon Vision LLC | $296.73 | 2020-2025 | Rocklatan, Precision7 |
| Kala Pharmaceuticals, INC. | $293.08 | 2019-2021 | |
| Abbvie INC. | $270.35 | 2022-2025 | Lumigan, Alphagan P, Vuity |
| Allergan, INC. | $250.12 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $199.58 | 2019-2021 | |
| Biotissue Holdings INC. | $121.43 | 2022-2024 | |
| Aerie Pharmaceuticals, INC. | $114.26 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $111.29 | 2024-2025 | Xdemvy |
| Horizon Therapeutics Plc | $56.99 | 2021 | |
| Oyster Point Pharma, INC. | $51.94 | 2022-2023 | Tyrvaya |
| Harrow Eye, LLC | $47.03 | 2024 | Vevye |
| Rxsight INC | $43.84 | 2021-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge, Rxsight Injector Handpiece |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $37.78 | 2023-2025 | Idosetr |
| Sight Sciences, INC. | $33.80 | 2019-2022 | |
| Dompe US, INC. | $20.12 | 2021 | |
| Johnson & Johnson Vision Care, INC. | $18.09 | 2022 | |
| Tearlab Corp | $17.76 | 2022 | |
| Shire North American Group INC | $17.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Byron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.